Oct 19, 2016
Janssen Pharmaceuticals, Inc. has announced that the Food and Drug Administration (FDA) of U.S. has approved VERMOXTM CHEWABLE (mebendazole chewable 500mg tablets) for treating patients, both adults and children, with gastrointestinal infections caused by Trichuris trichiura (whipworm) and Ascaris lumbricoides (roundworm). Around the world, this new tablet formulation can provide alternative treatment for millions of children infected by intestinal worms.
“Roundworm and whipworm are among the most prevalent forms of intestinal parasitic infections afflicting children in the world today, particularly in vulnerable and neglected communities. The FDA approval of VERMOXTM CHEWABLE represents an important milestone in our efforts to develop a new therapy that safely cures patients with intestinal infections by roundworm and whipworm. We will work with the World Health Organization (WHO), other health authorities and partners to ensure VERMOXTM CHEWABLE is available as part of our longstanding global product donation program,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson.
Dr. David Addiss, Director of Children Without Worms (CWW), a partnership between Johnson & Johnson, GSK and The Task Force for Global Health, said: “Roundworm and whipworm infect millions of children, most without reliable access to safe drinking water and good sanitation. A chewable form of mebendazole fills a major gap in global treatment efforts against intestinal worms and helps us treat children when they are most vulnerable to these debilitating infections.”